PRESIDENT DONALD TRUMP ANNOUNCES MOST FAVORED NATION PRICING ON PRESCRIPTION MEDICATIONS TO US PATIENTS

National News - In a significant move to address the longstanding issue of prescription drug pricing, an executive order has been issued to provide most-favored-nation (MFN) pricing for prescription drugs to American patients.

This action responds to a troubling disparity: while Americans make up less than five percent of the world's population, they account for approximately three-quarters of global pharmaceutical profits.

This imbalance arises from the practice of drug manufacturers offering heavily discounted prices to foreign markets while charging excessively high prices in the United States. As a result, American consumers end up subsidizing global pharmaceutical research and development.

The new executive order aims to rectify this situation by ensuring that Americans have access to prescription drugs at prices comparable to those in other developed nations.

The policy is clear: Americans should not have to shoulder the burden of subsidizing low-cost prescription drugs in other countries while paying higher prices themselves. Therefore, the administration is taking immediate steps to enable Americans to receive the most-favored-nation pricing on pharmaceuticals.

To prevent foreign nations from benefiting unjustly from American-funded innovation, measures will be taken to stop practices that unfairly pass on excessive research and development costs to American patients.

Furthermore, direct-to-consumer sales programs will be developed to allow Americans to purchase drugs at the most-favored-nation price.

Establishing MFN pricing will require coordination among several governmental entities to communicate pricing targets to pharmaceutical manufacturers. If significant progress is not achieved, further actions-such as regulatory measures and the potential importation of lower-cost prescription drugs-will be considered.

Additionally, enforcement actions against anti-competitive practices will be evaluated to ensure fair pricing.

This executive order represents a crucial step toward reducing drug costs for American patients, ensuring they no longer pay more than their counterparts in other developed nations.